Milestone Pharmaceuticals Inc.
MIST- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001408443
No open-market purchases or sales by Milestone Pharmaceuticals Inc. insiders were filed in the last 90 days; 78 institutions reported holding it in 13F filings for Q2 2026, worth $68.1M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Milestone Pharmaceuticals Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Milestone Pharmaceuticals Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Papa Joseph C | Director | 100,000 | Jun 12, 2026 | 1 |
| Giles Lisa M. | Director | – | Jun 12, 2026 | 1 |
| Tomsicek Michael John | Director | 15,000 | Jun 12, 2026 | 1 |
| Fischer Seth H. Z. | Director | – | Jun 12, 2026 | 1 |
| Saik Andrew | Director | – | Jun 12, 2026 | 1 |
| Wills Robert James | Director | 65,000 | Jun 12, 2026 | 1 |
| Duty Stuart | Director | – | Jun 12, 2026 | 1 |
| Oliveto Joseph | President and CEO | 446,244 | Apr 20, 2026 | 4 |
| Muller Lorenz | Chief Commercial Officer | 205,406 | Feb 5, 2026 | 3 |
| Hasija Amit | CFO & EVP of Corp. Development | 99,848 | Feb 5, 2026 | 2 |
| Bharucha David | Chief Medical Officer | 113,181 | Feb 5, 2026 | 2 |
| Nelson Jeffrey Edward | Chief Operating Officer | 49,848 | Feb 5, 2026 | 2 |
| Liebert Debra K. | Director | 16,793 | Jul 15, 2025 | 0 |
| Pasternak Richard C | Director | 10,000 | Jun 9, 2023 | 0 |
| RTW Investments, LP | 10% Owner | 3,256,102Indirect | Mar 24, 2023 | 0 |
| Wong Roderick | 10% Owner | 3,256,102Indirect | Mar 24, 2023 | 0 |
| Truex Paul F | Director | 81,780 | Jun 1, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 20, 2026 (view filing) | Apr 16 | 4 days | Oliveto JosephPresident and CEO | SSale | −36.5K | $2.26 | −$82.5K | −7.6%446.2K after | 10b5-1 |
| Jan 28, 2026 (view filing) | Dec 15, 2025-Jan 26, 2026 | 44 daysLate | Nelson Jeffrey EdwardChief Operating Officer | SSale | −70.3K | $2.25 | −$158.2K | −58.5%49.8K after | 2 lots |
| Jan 28, 2026 (view filing) | Dec 15, 2025-Jan 26, 2026 | 44 daysLate | Bharucha DavidChief Medical Officer | SSale | −70.3K | $2.25 | −$158.2K | −38.3%113.2K after | 2 lots |
| Jan 28, 2026 (view filing) | Dec 15, 2025-Jan 26, 2026 | 44 daysLate | Hasija AmitCFO & EVP of Corp. Development | SSale | −70.3K | $2.25 | −$158.2K | −41.3%99.8K after | 2 lots |
| Jan 28, 2026 (view filing) | Dec 15, 2025-Jan 26, 2026 | 44 daysLate | Muller LorenzChief Commercial Officer | SSale | −64.7K | $2.25 | −$145.9K | −24.0%205.4K after | 2 lots |
| Jan 28, 2026 (view filing) | Dec 15, 2025-Jan 26, 2026 | 44 daysLate | Oliveto JosephPresident and CEO | SSale | −167.6K | $2.24 | −$375.3K | −25.8%482.7K after | 2 lots |
| Jan 9, 2026 (view filing) | Jan 7-8 | 2 days | Oliveto JosephPresident and CEO | SSale | −43.5K | $2.25 | −$97.9K | −12.5%303.7K after | 2 lots10b5-1 |
| Dec 5, 2022 (view filing) | Dec 1-5 | 4 days | Bharucha DavidChief Medical Officer | PPurchase | +10.0K | $4.74 | +$47.4K | New position10.0K after | 2 lots |
| Oct 21, 2022 (view filing) | Oct 19 | 2 days | Wills Robert JamesDirector | PPurchase | +15.0K | $4.93 | +$74.0K | New position15.0K after | |
| Oct 21, 2022 (view filing) | Oct 20 | 1 day | Pasternak Richard CDirector | PPurchase | +10.0K | $5.20 | +$52.0K | New position10.0K after | |
| Oct 21, 2022 (view filing) | Oct 20-21 | 1 day | Liebert Debra K.Director | PPurchase | +14.0K | $5.28 | +$73.9K | New position4.00K after | 2 lots |
| Oct 21, 2022 (view filing) | Oct 19 | 2 days | Tomsicek Michael JohnDirector | PPurchase | +15.0K | $5.32 | +$79.8K | New position15.0K after | |
| Sep 9, 2022 (view filing)4:15 PM ET | Sep 7 | 2 days | RTW Investments, LP and 1 other10% Owner | PPurchaseCommon Shares, no par value ("Common Shares") | +1.56M | $8.71 | +$13.6M | +56.5%4.32M after | |
| Sep 9, 2022 (view filing)4:15 PM ET | Sep 7 | 2 days | RTW Investments, LP and 1 other10% Owner | SSale | −1.56M | $8.71 | −$13.6M | −26.5%4.32M after | |
| Jun 1, 2022 (view filing) | May 31 | 1 day | Truex Paul FDirector | PPurchase | +5.00K | $5.60 | +$28.0K | +6.5%81.8K after |